# Electrochemical Catheter Hub Operated by a Wearable Micropotentiostat Prevents Acinetobacter baumannii Infection In Vitro

**Authors:** Majid Al‐Qurahi, Derek Fleming, Won‐Jun Kim, Ibrahim Bozyel, Robin Patel, Haluk Beyenal

PMC · DOI: 10.1002/bit.28990 · 2025-04-15

## TL;DR

A wearable device generates hypochlorous acid in catheter hubs to prevent Acinetobacter baumannii infection in a lab setting.

## Contribution

A nonantibiotic, wearable micropotentiostat-powered electrochemical catheter hub is developed to prevent catheter-related infections.

## Key findings

- e-catheter hubs operated at 1.5 VAg/AgCl for 3 hours reduced A. baumannii below detection limits.
- HOCl generation via the e-catheter hub achieved biocidal activity comparable to commercial potentiostats.

## Abstract

Intraluminal infection of central venous catheters, used for long‐term treatment, can result in central line‐associated bloodstream infection (CLABSI). These infections can be challenging to prevent and treat due to formation of biofilms within catheter lumens, which shield bacteria from the human immune response and conventional antimicrobial therapies. Preventing bacterial colonization of catheter hubs is a strategy to prevent CLABSI. To address this, we developed a nonantibiotic, animal‐ready electrochemical catheter hub (e‐catheter hub), operated by a wearable, battery‐powered micropotentiostat (MP), that internally generates tunable hypochlorous acid (HOCl) for preventing intraluminal infection. The design evaluated three different electrode materials—titanium, platinum, and gold—for HOCl generation and biocidal activity, using working and counter electrodes of the same materials and a silver/silver chloride‐plated wire as a quasi‐reference electrode. e‐catheter hubs operated by MPs at 1.5 VAg/AgCl for 3 h generated HOCl, reducing Acinetobacter baumannii ATCC‐17978 below the detection limit (average reduction of 4.40 ± 0.05 log10 CFU/mL). The efficacy of e‐catheter hubs operated by MPs in generating HOCl and achieving biocidal activity is comparable to that of a commercial potentiostat. This study represents the first step in developing a localized, nonantibiotic strategy to mitigate CLABSI risk.

## Linked entities

- **Chemicals:** hypochlorous acid (PubChem CID 24341), HOCl (PubChem CID 24341)
- **Species:** Acinetobacter baumannii (taxon 470)

## Full-text entities

- **Diseases:** infection (MESH:D007239), Acinetobacter baumannii Infection (MESH:D000151), CLABSI (MESH:D018805)
- **Chemicals:** platinum (MESH:D010984), silver (MESH:D012834), AgCl (MESH:C037548), HOCl (MESH:D006997), titanium (MESH:D014025)
- **Species:** Acinetobacter baumannii ATCC 17978 (strain) [taxon 400667], Homo sapiens (human, species) [taxon 9606]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12152523/full.md

---
Source: https://tomesphere.com/paper/PMC12152523